Syn lett

D. Nakajima et al.

# Synthesis of Majusculamides A and B

Daisuke Nakajima<sup>a</sup> Kosuke Sueyoshi<sup>b</sup> Kensuke Orihara<sup>a</sup> Toshiaki Teruya<sup>\*b</sup> Satoshi Yokoshima<sup>\*a</sup> <sup>(D)</sup>

<sup>a</sup> Graduate School of Pharmaceutical Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan

yokosima@ps.nagoya-u.ac.jp <sup>b</sup> Faculty of Education, University of Ryukyus, 1 Senbaru, Nishihara,

Okinawa, 903-0213, Japan t-teruva@edu.u-rvukvu.ac.ip

Received: 28.02.2019 Accepted after revision: 02.04.2019 Published online: 12.04.2019 DOI: 10.1055/s-0037-1611805; Art ID: st-2019-u0118-l

**Abstract** The synthesis of two marine lipodipeptides, majusculamides A and B, is described. The key feature of this synthesis is the stereoselective construction of an  $\alpha$ -methyl- $\beta$ -keto-carboxamide moiety.

**Key words** marine natural products, peptides, polyketides,  $\beta$ -ketoamide, asymmetric aldol reaction

Marine natural products show a wide range of biological activities because of their structural diversity, which offers a rich source of biological tools as well as new drugs.<sup>1</sup> Although the evaluation of their biological activities is sometimes restricted by their limited natural supply, chemical synthesis can provide sufficient amounts of samples and might expand the possibility of identifying the potencies of the molecules. In connection with our campaign to discover biologically active molecules, we developed syntheses of the marine natural products, majusculamides A and B (Figure 1).



The first isolation of the majusculamides from cyanobacteria, *Lyngbya majuscula*, and their structural elucidation were reported by Moore, Clardy, and co-workers in 1977.<sup>2.3</sup> These natural products feature a dipeptide moiety



Letter

comprising *N*,*O*-dimethyl-D-tyrosine and *N*-methyl-L-valine, with a C-terminal primary amide. The  $\alpha$ -methyl- $\beta$ keto-decanoyl group is bonded to the N terminus of the dipeptide to form a tertiary amide. The methyl group in the decanoyl group generates two diastereomers, and the (*R*) and (*S*) diastereomers are majusculamides A (**1**) and B (**2**), respectively.

Although the  $\alpha$ -methyl- $\beta$ -keto-carboxamide moiety appears to be stereochemically labile, these two isomers could be separated. Isomerization of either isomer under heating in dimethyl sulfoxide at 140 °C was reported to be slow.<sup>4,5</sup> Conformational insights into the  $\alpha$ -methyl- $\beta$ -keto-imide moiety by Evans and coworkers explain the stereochemical stability of the system,<sup>6</sup> in which the C–H bond at the  $\alpha$  position is arranged almost coplanar with the plane of the amide so as to minimize the 1,3-allylic strain of the amide moiety (Figure 2).<sup>7,8</sup> This insight also suggests that the alkyl chains of the decanoyl groups in majusculamides A and B are oriented in different directions relative to the dipeptide core in preferable conformations, thereby differentiating the shapes of the two molecules.<sup>9</sup> The structural differences might confer distinct biological activities. In fact, a difference in cell cytotoxicity measured with an MTT assay was observed between majusculamides A and B. Majusculamide A showed cytotoxicity at 10 µM in cultured Hela S3 cells, while majusculamide B showed no cytotoxicity under the same conditions.<sup>10</sup>

The synthesis of majusculamides A and B began with the preparation of methylated amino acid units (Scheme 1). Protection of D-tyrosine (**3**) with a Boc group,<sup>11</sup> followed by methylation with iodomethane in the presence of sodium hydride in tetrahydrofuran afforded *N*,*O*-dimethyl-*N*-Boctyrosine (**4**).<sup>12</sup> After protecting L-valine (**5**) with a Boc group, *N*-methylation was conducted under the same conditions.<sup>13</sup> The carboxylic acid moiety in **6** was then activated by treatment with isobutyl chloroformate and *N*-methSynlett

D. Nakaiima et al.

В



**Figure 2** Structural comparison of majusculamides A and B. The dipeptide core, shown in gray, is based on the X-ray crystal structure of majusculamide B. The alkyl chains, shown in green and violet for majusculamides A and B, respectively, are presented in extended forms.

vlmorpholine in diethyl ether, and the resulting mixed anhydride was treated with ammonia gas to furnish carboxamide 7.14 Compound 7 was subjected to deprotection by treatment with methanolic hydrogen chloride, giving the hydrogen chloride salt of N-methylvaline carboxamide 8. Condensation of these amino acid units thus obtained could be successfully carried out by using (1-cvano-2ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate (COMU) to give dipeptide 9 in 74% yield.<sup>15</sup> Employing other condensation reagents such as O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium-hexafluorophosphate (HATU) or EDCI-HOBt (EDCI = ethyl-3-(3-dimethylaminopropyl)carbodiimide) resulted in a lower yield because of the steric hindrance at the units. The Boc group in 9 was cleaved with methanolic hydrogen chloride to give **10**.

The decanoic acid unit was prepared by an asymmetric aldol reaction (Scheme 2). Sequential treatment of (R)-propanovloxazolidinone 11 with titanium(IV) chloride. TME-DA, and then octanal (12) afforded  $\beta$ -hydroxy-imide 13,<sup>16</sup> which was hydrolyzed with lithium hydroperoxide to give carboxylic acid 14.<sup>17</sup> Condensation of 14 with dipeptide 10 was conducted by using HATU to furnish 15 in 72% vield.<sup>18,19</sup> Since the primary carboxamide moiety in **10** was affected by HATU, premixing 14 and HATU before adding 10 effectively improved the yield. Finally, oxidation of the secondary alcohol moiety with Dess-Martin periodinane<sup>20</sup> in the presence of sodium bicarbonate produced majusculamide A (1).<sup>21</sup> Starting from (S)-propanoyloxazolidinone 16, majusculamide B (2) could be obtained according to the same procedure.<sup>22</sup> The spectral data of the synthetic materials were identical to those of the natural samples.

In summary, we achieved syntheses of majusculamides A and B with a longest linear sequence of eight steps in 13 and 18% overall yields, respectively. The characteristic  $\alpha$ -



**Scheme 1** Preparation of methylated amino acid units. *Reagents and conditions*: (a) Boc<sub>2</sub>O, NaOH, 1,4-dioxane–H<sub>2</sub>O, rt; (b) NaH, MeI, THF, 0 °C to rt, 84% (2 steps); (c) Boc<sub>2</sub>O, NaOH, THF–H<sub>2</sub>O, rt; (d) NaH, MeI, THF, 0 °C to rt; (e) *i*-BuOCOCI, *N*-methylmorpholine, Et<sub>2</sub>O, -15 °C; NH<sub>3</sub> (gas), -15 °C to rt, 50% (3 steps); (f) HCl, MeOH, 0 °C to rt, 98%; (g) **4**, COMU, DMF, 0 °C, then **8**, Et<sub>3</sub>N, 0 °C to rt, 74%; (h) HCl, MeOH, rt, quant.



**Scheme 2** Syntheses of majusculamides A and B. *Reagents and conditions*: (a) TiCl<sub>4</sub>, TMEDA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, then octanal (**12**), 0 °C, 68%; (b) LiOH·H<sub>2</sub>O, H<sub>2</sub>O<sub>2</sub>, THF–H<sub>2</sub>O, 0 °C, quant.; (c) **14**, HATU, *i*-Pr<sub>2</sub>NEt, DMF, 0 °C, then **10**, 0 °C to rt, 72%; (d) Dess–Martin periodinane, NaHCO<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 51%

methyl- $\beta$ -keto-carboxamide moiety could be constructed in a two-step sequence, which includes condensation of the amine moiety in the peptide unit and the  $\beta$ -hydroxy-car-

Letter

#### D. Nakajima et al.

boxylic acid units, followed by oxidation of the hydroxy group. The sequence can be used to synthesize analogues of majusculamides. Other biological evaluation of the natural products and the analogues is currently underway and will be reported in due course.

## **Funding Information**

This work was financially supported by JSPS KAKENHI (Grant Numbers 17H01523 and 18H04399) and by the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research; BINDS) from the Japan Agency for Medical Research and Development (AMED) under Grant Number JP18am0101099.

## **Supporting Information**

Supporting information for this article is available online at https://doi.org/10.1055/s-0037-1611805.

### **References and Notes**

- (a) Molinski, T. F.; Dalisay, D. S.; Lievens, S. L.; Saludes, J. P. Nat. Rev. Drug Discov. 2009, 8, 69. (b) Montaser, R.; Luesch, H. Future Med. Chem. 2011, 3, 1475. (c) Blunt, J. W.; Copp, B. R.; Keyzers, R. A.; Munro, M. H. G.; Prinsep, M. R. Nat. Prod. Rep. 2017, 34, 235. (d) Blunt, J. W.; Carroll, A. R.; Copp, B. R.; Davis, R. A.; Keyzers, R. A.; Prinsep, M. R. Nat. Prod. Rep. 2018, 35, 8. (e) Carroll, A. R.; Copp, B. R.; Davis, R. A.; Keyzers, R. A.; Prinsep, M. R. Nat. Prod. Rep. 2019, 36, 122.
- (2) Marner, F.-J.; Moore, R. E.; Hirotsu, K.; Clardy, J. J. Org. Chem. 1977, 42, 2815.
- (3) Majusculamides A and B were also recently isolated by us from the marine cyanobacterium *Moorea producens* collected from the coast of Bise Okinawa.
- (4) No isomerization was observed in <sup>1</sup>H NMR spectra of the pure amides in DMSO- $d_6$  at 140 °C after heating for 10 minutes.
- (5) The  $\alpha$ -methyl- $\beta$ -keto-carboxamide moiety is observed in the macrocyclic systems of some natural products. For synthetic studies toward such natural products, see: (a) Rinehart, K. L.; Kishore, V.; Nagarajan, S.; Lake, R. J.; Gloer, J. B.; Bozich, F. A.; Li, K.-M.; Maleczka, R. E.; Todsen, W. L.; Munro, M. H. G.; Sullins, D. W.; Sakai, R. J. Am. Chem. Soc. 1987, 109, 6846. (b) Plaza, A.; Garcia, R.; Bifulco, G.; Martinez, J. P.; Hüttel, S.; Sasse, F.; Meyerhans, A.; Stadler, M.; Müller, R. Org. Lett. 2012, 14, 2854. (c) Ghosh, A. K.; Rao, K. V.; Akasapu, S. Tetrahedron Lett. 2014, 55, 5191. (d) Qi, N.; Allu, S. R.; Wang, Z.; Liu, Q.; Guo, J.; He, Y. Org. Lett. 2016, 18, 4718. (e) Revu, O.; Prasad, K. R. J. Org. Chem. 2017, 82, 438. (f) Seo, C.; Yim, J. H.; Lee, H. K.; Park, S. M.; Sohn, J.-H.; Oh, H. Tetrahedron Lett. 2008, 49, 29. (g) Ghosh, A. K.; Xu, C.-X. Org. Lett. 2009, 11, 1963. (h) Reddy, K. M.; Shashidhar, J.; Pottireddygari, G. R.; Ghosh, S. Tetrahedron Lett. 2011, 52, 5987. (i) Kaneda, M.; Inuki, S.; Ohno, H.; Oishi, S. J. Org. Chem. 2018, 83.3047.
- (6) Evans, D. A.; Ennis, M. D.; Le, T.; Mandel, N.; Mandel, G. J. Am. Chem. Soc. 1984, 106, 1154.
- (7) Tertiary amides are essential for the stereochemical stabilities of β-keto-carboxamides. For examples of isomerization of secondary amides, see: (a) Satoh, N.; Yokoshima, S.; Fukuyama, T.

*Org. Lett.* **2011**, *13*, 3028. (b) Sun, Y.; Ding, Y.; Li, D.; Zhou, R.; Su, X.; Yang, J.; Guo, X.; Chong, C.; Wang, J.; Zhang, W.; Bai, C.; Wang, L.; Chen, Y. *Angew. Chem. Int. Ed.* **2017**, *56*, 14627.

- (8) In the case of N,O-dimethylhydroxamic acids, also known as Weinreb amides, α-methyl-β-keto compounds could be employed in further transformation under the appropriate conditions without isomerization, whereas the α-methyl-β-keto compounds could be used as substrates for asymmetric transfer hydrogenation with dynamic kinetic resolution. For examples, see: (a) Takamura, H.; Kadonaga, Y.; Kadota, I.; Uemura, D. *Tetrahedron* **2010**, *66*, 7569. (b) Kumaraswamy, G.; Narayanarao, V.; Shanigaram, P.; Balakishan, G. *Tetrahedron* **2015**, *71*, 8960.
- (9) The structure of the  $\alpha$ -methyl- $\beta$ -keto-carboxamide moiety was supported by DFT calculations and NOESY experiments of simplified molecules. For details, see Supporting Information.
- (10) Glucose uptake enhancement activity was also investigated. Both compounds had no effect on the glucose uptake up to a concentration of  $30 \,\mu\text{M}$  in cultured L6 myotubes.
- (11) Partial formation of an N,O-bis(Boc) product was observed under those conditions. The Boc group on the phenolic hydroxy group was easily cleaved during the ensuing methylation. For related reports, see: (a) Nakamura, K.; Nakajima, T.; Kayahara, H.; Nomura, E.; Taniguchi, H. *Tetrahedron Lett.* **2004**, *45*, 495. (b) Nishiyama, Y.; Ishizuka, S.; Shikama, S.; Kurita, K. *Chem. Pharm. Bull.* **2001**, *49*, 233.
- (12) Boger, D. L.; Yohannes, D. J. Org. Chem. 1988, 53, 487.
- (13) Malkov, A. V.; Vranková, K.; Černý, M.; Kočovský, P. J. Org. Chem.
   2009, 74, 8425.
- (14) Lim, H. J.; Gallucci, J. C.; RajanBabu, T. V. Org. Lett. **2010**, *12*, 2162.
- (15) El-Faham, A.; Funosas, R. S.; Prohens, R.; Albericio, F. Chem. Eur. J. 2009, 15, 9404.
- (16) Crimmins, M. T.; King, B. W.; Tabet, E. A. J. Am. Chem. Soc. **1997**, *119*, 7883.
- (17) (a) Evans, D. A.; Sjogren, E. B.; Bartroli, J.; Dow, R. L. *Tetrahedron Lett.* **1986**, *27*, 4957. (b) Evans, D. A.; Britton, T. C.; Ellman, J. A. *Tetrahedron Lett.* **1987**, *28*, 6141.
- (18) (a) Carpino, L. A. J. Am. Chem. Soc. **1993**, *115*, 4397. (b) Carpino,
  L. A.; Imazumi, H.; El-Faham, A.; Ferrer, F. J.; Zhang, C.; Lee, Y.;
  Foxman, B. M.; Henklein, P.; Hanay, C.; Mügge, C.; Wenschuh,
  H.; Klose, J.; Beyermann, M.; Bienert, M. Angew. Chem. Int. Ed. **2002**, *41*, 441.
- (19) (2R,3S)-N-[(R)-1-{[(S)-1-amino-3-methyl-1-oxobutan-2yl](methyl)amino}-3-(4-methoxyphenyl)-1-oxopropan-2yl]-3-hydroxy-N,2-dimethyldecanamide (15)

To a solution of carboxylic acid 14 (51.0 mg, 0.252 mmol) and *i*-Pr<sub>2</sub>NEt (0.048 mL, 0.28 mmol) in DMF (1.62 mL) was added HATU (106 mg, 0.278 mmol) at 0 °C. After stirring for 30 min, a solution of amine hydrochloride 10 (90.3 mg, 0.252 mmol) and i-Pr<sub>2</sub>NEt (0.097 mL, 0.56 mmol) in DMF (1.54 mL) was added dropwise at 0 °C. After the resulting mixture was stirred for 4 h at 25 °C, the reaction was guenched with NaCl solution (10%) in water. The resulting mixture was extracted three times with AcOEt. The combined organic phases were washed with aqueous NaHCO<sub>3</sub>, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (AcOEt-n-hexane 1:5 to 1:0) to give 15 (91.4 mg, 0.181 mmol, 72%) as a colorless oil.  $[\alpha]_D^{23}$  -1.78 (c 0.310, CHCl<sub>3</sub>). IR (film): 3397, 3205, 2929, 2856, 1691, 1627, 1514, 1466, 1405, 1301, 1249, 1178, 1095, 1036, 824 cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, mixture of rotamers):  $\delta = [7.14 (d, J = 8.8)]$ Hz), 7.10 (d, J = 8.8 Hz), all sum to 2 H), [6.81 (d, J = 8.8 Hz), 6.79 (d, J = 8.8 Hz), all sum to 2 H], [6.71 (br s), 6.13 (br s), all sum to 1

H], [5.70 (dd, J = 8.0, 7.6 Hz), 5.68 (dd, J = 8.0, 7.6 Hz), all sum to 1 H], [5.58 (br s), 5.35 (br s), all sum to 1 H], [4.50 (d, <math>I = 10.8 Hz),3.72 (d, J = 10.4 Hz), all sum to 1 H], 3.80-3.60 (m, 1 H), 4.15-4.06 (br s, 1 H), [3.76 (s), 3.76 (s), all sum to 3 H], 3.18-2.84 (m, 2 H), [some signals including the following: 3.06 (s), 2.99 (s), 2.96 (s), 2.91 (s), all sum to 6 H], [2.57 (qd, J = 7.2, 2.0 Hz), 2.48 (qd, *I* = 7.2, 2.0 Hz), 1 H], 2.34–2.15 (m, 1 H), 1.48 (m, 2 H), 1.34–1.17 (m, 10 H), [0.97 (d, I = 6.4 Hz), 0.74 (d, I = 6.4 Hz), all sum to 3 H],[0.93–0.81 (m), 0.65 (d, J = 6.4 Hz), 0.63 (d, J = 6.4 Hz), 6 H], 0.89 (t, J = 7.7 Hz, 3 H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, mixture of rotamers): δ = 178.6 (C), 178.1 (C), 172.1 (C), 171.8 (C), 171.6 (C), 169.1 (C), 158.6 (C), 158.5 (C), 130.3 (CH), 130.1 (CH), 128.2 (C), 128.0 (C), 113.9 (CH), 113.8 (CH), 71.2 (CH), 70.8 (CH), 63.5 (CH), 62.4 (CH), 55.3 (CH<sub>3</sub>), 54.3 (CH), 53.9 (CH), 39.4 (CH), 39.0 (CH), 34.7 (CH<sub>2</sub>), 34.6 (CH<sub>2</sub>), 33.9 (CH<sub>2</sub>), 33.5 (CH<sub>2</sub>), 31.8 (CH<sub>2</sub>), 31.1 (CH<sub>3</sub>), 31.0 (CH<sub>3</sub>), 30.7 (CH<sub>3</sub>), 30.4 (CH<sub>3</sub>), 29.6 (CH<sub>2</sub>), 29.2 (CH<sub>2</sub>), 27.3 (CH), 26.0 (CH<sub>2</sub>), 25.9 (CH<sub>2</sub>), 25.4 (CH), 22.6 (CH<sub>2</sub>), 19.7 (CH<sub>3</sub>), 19.3 (CH<sub>3</sub>), 19.2 (CH<sub>3</sub>), 18.3 (CH<sub>3</sub>), 14.1 (CH<sub>3</sub>), 9.3 (CH<sub>3</sub>), 8.5 (CH<sub>3</sub>). HRMS (ESI+): m/z calcd for C<sub>28</sub>H<sub>47</sub>N<sub>3</sub>NaO<sub>5</sub>: 528.3413; found: 528.3427.

(20) (a) Dess, D. B.; Martin, J. C. J. Org. Chem. 1983, 48, 4155. (b) Dess,
 D. B.; Martin, J. C. J. Am. Chem. Soc. 1991, 113, 7277.

#### (21) Majusculamide A (1)

To a solution of  $\beta$ -hydroxy amide **15** (26.1 mg, 0.0517 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (0.344 mL), were added NaHCO<sub>3</sub> (8.15 mg, 0.0971 mmol) and Dess-Martin periodinane (32.9 mg, 0.0775 mmol) at 0 °C. After stirring for 1 h at 25 °C, NaHCO<sub>3</sub> aq and Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> aq were added to the reaction mixture. The resulting solution was extracted three times with AcOEt. The combined organic layer was dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude product was purified by preparative TLC (AcOEt-*n*-hexane 5:1) to give **1** (13.3 mg, 0.0264 mmol, 51%) as a colorless oil. [α]<sub>D</sub><sup>23</sup> +33.2 (*c* 0.715, EtOH). IR (film): 3335, 3208, 2930, 2863, 1688, 1635, 1510, 1463, 1400, 1297, 1250, 1178, 1107, 1040, 829 cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, mixture of rotamers): δ [7.14 (d, J = 8.4 Hz), 7.08 (d, J = 8.4 Hz), all sum to 2 H], [7.01 (br s), 6.16 (br s), all sum to 1 H], [6.80 (d, J = 8.4 Hz), 6.79 (d, J = 8.4 Hz), all sum to 2 H], [5.71 (dd, J = 8.0, 8.0 Hz), 5.65 (dd, J = 9.2, 6.0 Hz), all sum to 1 H], [5.50 (br s), 5.27 (br s), all sum to 1 H], [4.54 (d, J = 10.8), 3.71 (d, J = 10.8 Hz), all sum to 1 H], 3.77 (s, 3 H), [3.59 (q, J = 7.0 Hz), 3.44 (q, J = 7.2 Hz), all sum to 1 H], 3.20-2.85 (m, 2 H), [some signals including the following: 3.08 (s), 3.00 (s), 2.94 (s), 2.91 (s), all sum to 6 H], 2.48-2.30 (m, 2 H), [2.34-2.24 (m), 2.26-2.14 (m), all sum to 1 H], 1.51 (m, 2 H), 1.35-1.10 (m, 8 H), [1.00-0.91 (m), 0.90-0.78 (m) 0.59 (d, J = 6.4 Hz), all sum to 6 H], [1.22 (d, J = 7.0 Hz), 0.93 (d, J = 7.0Hz), all sum to 3 H] 0.85 (m, 3 H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, mixture of rotamers):  $\delta$  = 206.9 (C), 206.7 (C), 172.5 (C), 172.0 (C), 171.7 (C), 171.6 (C), 171.2 (C), 169.3 (C), 158.5 (C), 130.3 (CH), 130.1 (CH), 128.3 (C), 128.2 (C), 113.9 (CH), 113.8 (CH), 63.7 (CH), 62.5 (CH), 55.7 (CH), 55.3 (CH<sub>3</sub>), 54.3 (CH), 51.2 (CH), 50.6 (CH), 40.5 (CH<sub>2</sub>), 40.1 (CH<sub>2</sub>), 34.9 (CH<sub>2</sub>), 34.6 (CH<sub>2</sub>), 31.6 (CH<sub>2</sub>), 31.2 (CH<sub>3</sub>), 30.9 (CH<sub>3</sub>), 30.7 (CH<sub>3</sub>), 29.6 (CH<sub>3</sub>), 29.1 (CH<sub>2</sub>), 27.6 (CH), 25.5 (CH), 23.5 (CH<sub>2</sub>), 23.3 (CH<sub>2</sub>), 22.6 (CH<sub>2</sub>), 19.9 (CH<sub>3</sub>), 18.8 (CH<sub>3</sub>), 18.6 (CH<sub>3</sub>), 18.4 (CH<sub>3</sub>), 14.1 (CH<sub>3</sub>), 13.4 (CH<sub>3</sub>). HRMS (ESI+): *m/z* calcd for C<sub>28</sub>H<sub>45</sub>N<sub>3</sub>NaO<sub>5</sub>: 526.3257; found: 526.3252.

#### (22) Majusculamide B (2)

To a solution of  $\beta$ -hydroxy amide (17.6 mg, 0.0348 mmol), prepared by condensation of *ent*-14 with 10, in CH<sub>2</sub>Cl<sub>2</sub> (0.232 mL), were added NaHCO<sub>3</sub> (4.8 mg, 0.0568 mmol) and Dess-Martin periodinane (19.2 mg, 0.0453 mmol) at 0 °C. After stirring for 1 h at 25 °C, NaHCO<sub>3</sub> ag and Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> ag were added to the reaction mixture. The resulting solution was extracted three times with AcOEt. The combined organic layer was dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude product was purified by preparative TLC (AcOEt-n-hexane 5:1) to give 2 (10.8 mg, 0.0215 mmol, 62%) as a colorless oil.  $[\alpha]_{D}^{23}$  +25.5 (c 0.580, EtOH). IR (film): 3336, 3209, 2958, 2931, 2856, 1722, 1691, 1633, 1514, 1467, 1400, 1301, 1249, 1178, 1128, 1101, 1073, 1038, 825 cm<sup>-1</sup>, <sup>1</sup>H NMR (400 MHz, CDCl<sub>2</sub>, mixture of rotamers):  $\delta = [7.16 (d, J = 8.6 Hz), 7.12 (d, J = 8.6 Hz), all sum to$ 2 H], [6.80 (d, J = 8.6 Hz), 6.78 (d, J = 8.4 Hz), all sum to 2 H], [6.74 (br s), 6.09 (br s), all sum to 1 H], [5.77 (dd, J = 7.4, 7.4 Hz), 5.73 (dd, J = 8.8, 6.4 Hz), all sum to 1 H], [5.48 (br s), 5.32 (br s), all sum to 1 H], [4.48 (d, J = 10.8 Hz), 3.62 (d, J = 10.8 Hz), all sum to 1 H], [3.76 (s), 3.75 (s), all sum to 3 H], 3.61-3.43 (m, 1 H), 3.18-2.85 (m, 2 H), [some signals including the followings: 3.04 (s), 3.04 (s), 3.02 (s), 2.91 (s), all sum to 6 H], 2.32-2.15 (m, 1 H), [1.99 (dt, J = 17.6, 7.2 Hz), 1.93 (dt, J = 17.6, 7.2 Hz), 1.65–1.53 (m), all sum to 2 H], 1.50-1.32 (m, 2 H), 1.32-1.06 (m, 8 H), 1.28 (d, J = 7.2 Hz, 3 H), [0.97 (d, J = 6.4 Hz), 0.92 (d, J = 6.4 Hz), 0.91-0.84 (m), 0.75 (d, J = 6.8 Hz), 0.63 (d, J = 6.8 Hz), all sum to 6 H], 0.88 (t, J = 7.2 Hz, 3 H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, mixture of rotamers): δ = 206.6 (C), 205.5 (C), 172.2 (C), 171.8 (C), 171.5 (C), 171.4 (C), 171.0 (C), 169.2 (C), 158.5 (C), 130.3 (CH), 130.1 (CH), 128.3 (C), 113.9 (CH), 63.7 (CH), 62.4 (CH), 55.1 (CH<sub>3</sub>), 55.0 (CH<sub>3</sub>), 54.9 (CH), 54.3 (CH), 51.4 (CH), 50.7 (CH), 39.4 (CH<sub>2</sub>), 39.3 (CH<sub>2</sub>), 34.8 (CH<sub>2</sub>), 34.6 (CH<sub>2</sub>), 31.2 (CH<sub>2</sub>), 31.6 (CH<sub>3</sub>), 30.9 (CH<sub>3</sub>), 30.5 (CH<sub>2</sub>), 29.5 (CH<sub>2</sub>), 29.2 (CH<sub>2</sub>), 29.1 (CH<sub>2</sub>), 29.0 (CH<sub>2</sub>), 28.9 (CH<sub>2</sub>), 27.4 (CH), 25.4 (CH), 23.4 (CH<sub>2</sub>), 23.4 (CH<sub>2</sub>), 22.6 (CH<sub>2</sub>), 19.7 (CH<sub>3</sub>), 19.2 (CH<sub>3</sub>), 19.2 (CH<sub>3</sub>), 18.3 (CH<sub>3</sub>), 14.1 (CH<sub>3</sub>), 13.7 (CH<sub>3</sub>), 13.6 (CH<sub>3</sub>). HRMS (ESI+): m/z calcd for C<sub>28</sub>H<sub>45</sub>N<sub>3</sub>NaO<sub>5</sub>: 526.3257; found: 526.3278.